AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 SEP 10 - (NewsRx.com & NewsRx.net) -- Combined systemic and mucosal vaccination with the recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) enhanced immunogenicity in humans.
"We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) in 12 healthy volunteers," researchers in Germany report.
"The systemic booster induced higher levels of OprF-I-specific serum antibodies of IgG isotype, with a mean[+ or -]S.E.M. of 32.6[+ or -]7.8 X 10[superscript]7 enzyme-linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6[+ or -]2.1 x 10[superscript]7 EU (p=0.05)," stated Kerstin Gocke and collaborators at Hannover Medical School, Freiburg University, and MediGene. "Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups."
"We conclude that a combined mucosal/systemic vaccination with the OprF-I vaccine may offer an enhanced ...
Source: HighBeam Research, Combined systemic and mucosal OprF-I vaccination enhances...